Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Cadila Healthcare may test Rs 435: Anand Rathi

31 December, 2018 6:43 AM
94 0
Cadila Healthcare may test Rs 435: Anand Rathi

Cadila Healthcare is one of the top three in gynaecology, respiratory, pain management, CVS and dermatology.

and earnings ahead. On the high base, we expect 8 percent and 9 percent CAGRs over FY18-21 in revenue and earnings respectively.

The company expects 40-50 launches annually and is focusing on vaccines and biologics – which could be future growth drivers.

It has strong ANDA pipeline in the US, with 144 filings awaiting approval of which 60+ are Para IV. It launched 20 products in the year,

including g Lialda and gTamiflu and received 77 approvals in FY18, bringing cumulative filings/approvals to 330/186.

The company has recently announced it is considering fund raising proposals of up to Rs 10,000 Cr via QIP & up to Rs 5,000 cr via FCCBs.

Source: moneycontrol.com

Share in social networks:

Comments - 0